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1. Introduction
Celiac disease, in one sentence, can probably be defined as a complex autoimmune 
disorder triggered by gluten ingestion in people carrying the HLA-DQ2 or HLA-DQ8 
gene. The most common symptom associated with the disease is diarrhea after eating 
gluten-containing food, such as wheat, rye, or barley products. The earliest docu-
mentation about the celiac disease can be traced back to the 2nd century AD and it 
was written by a Greek physician named Aretaeus the Cappadocian [1]. He used the 
Greek word “koiliakos” or “coeliacs” to call it, meaning abdomen discomfort. He said 
in English translation: “If the stomach be irretentive of food and if it passes through 
undigested and crude, and nothing ascends into the body, we call such persons 
coeliacs”. He also identified the connection between the illness and eating bread and 
learned that fasting was helpful to reduce the symptoms. This knowledge was elabo-
rated 1700 years later by a British doctor, Samuel Jones Gee, in his lecture entitled 
“On the Celiac Affection” [2]. He revealed the fact that celiac disease could affect 
not only children but also adults, but mostly children under 5 years old. If the patient 
must eat bread, he suggested, “Bread cut thin and well toasted on both sides … But if 
the patient can be cured at all, it must be by means of diet”. This is consistent with our 
knowledge today. A more interesting description about the celiac disease was found in 
the three lectures given by Professor George F. Still at the Royal College of Physicians 
of London [3], who vividly pictured his observation of the sick children: “What 
appears to be an infant little more than 12 months old … it is at least a year or two 
older, perhaps three or four years older, than its appearance would suggest”. Now we 
know that this is due to malnutrition associated with such eating disorders. Another 
important discovery was made by Dicke, a Dutch pediatrician, who noticed that celiac 
disease almost vanished in the Netherlands during World War II when bread was 
on a serious scarcity, but it came back quickly when the Swedish airplanes dropped 
bread to the region. Later, he figured out that it was gluten that made people sick [4]. 
Starting from the mid-20th century, people have been developing various endoscopic 
tools to reach into the duodenum or even further down into the small intestine to 
obtain tissue samples for pathological analysis. This technology significantly acceler-
ated our understanding of the pathogenesis of the celiac disease [5]. Later on, gluten 
antibodies were discovered in patients with celiac disease and their diagnostic value 
was soon recognized in the medical community [6]. This work built the founda-
tion for serological detection of celiac disease today. From the 70s, people started to 
look for the possible genetic reasons for celiac disease, and soon a connection with 
HLA-DQ2 and HLA-DQ8 expression was found [7, 8]. After the 90s, our current 
concept of celiac disease was gradually formed: this is an autoimmune disorder that 
can be triggered by gluten ingestion in people with a DQ2 or DQ8 genetic background.
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Looking back the history, our understanding of celiac disease has experienced 
such path: presentations of the disease (ancient time till 19th century) – identifi-
cation of gluten as the cause (mid-20th century) – pathology of the disease (the 
50-the 60s) – immunology of the disease (the 60–70s) – genetics of the disease (the 
70–80s) – current concept of the disease (after the 90s).
2. Pathogenesis of celiac disease
Gluten is a common name for the viscoelastic proteins present in various grains, 
such as gliadin from wheat, hordein from barley, and secaline from rye. The main 
amino acids of these proteins are glutamine and proline (or collectively called 
prolamine), which makes them resistant to proteolytic enzymes of the human gut. 
Using gliadin as an example, gliadin contains 35% glutamine and 15% proline and 
can only be broken down to oligopeptides of 20–50 amino acids in the human intes-
tine. For the majority of people, these peptides remain in the lumen of the intestine 
and eventually are expelled out from the body, but for those individuals who carry 
HLA-DQ2/DQ8 genes, they can bind to the chemokine receptor CXCR3 on the 
intestinal epithelial cells to induce zonulin overexpression. Zonulin in structure is 
similar to the zona occludens toxin from Vibrio cholera and has the function to dis-
assemble the tight junctions between epithelial cells via protease activated receptor 
2/EGFR pathway. This allows the half-digested gluten peptides to pass through the 
mucosal barrier and reach the lamina propria [9]. Gluten peptides can also reach the 
lamina propria through the epithelial cells using IgA/CD71 channels. Once getting 
into the lamina propria, these peptides are deamidated by tissue transglutaminase 2 
(tTG2), converting glutamine to glutamate, which makes them easier to be taken up 
by HLA-DQ2 and –DQ8 bearing antigen-presenting cells. This triggers the genera-
tion of gluten-specific CD4+ T lymphocytes [10]. Upon gluten stimulation, these 
gluten-specific T cells start to produce a lot of pro-inflammatory cytokines, includ-
ing interleukin (IL)-15, IL-21, and interferon-γ. IL-15 stimulates CD8+ T cells to 
migrate to the epithelial layer to attack the epithelial cells, causing villous atrophy, a 
hallmark of celiac disease [11]. Gluten-specific T cells also promote the activation of 
B cells, which develop into plasma cells, producing the autoantibodies against tTG2, 
which is used nowadays as the biomarker in serological tests for celiac disease [12].
Although all of the celiac disease patients are either DQ2 or DQ8 positive, only 
1–3% of the people with such genetic background develop the disease [13, 14], indi-
cating that other factors must be involved. Microbial infection in the duodenum has 
been postulated to play a role. For instance, Pseudomonas aeruginosa, a bacteria that 
is commonly found in the duodenum of celiac disease patients, produces elastases 
that can degrade the gluten into highly immunogenic peptides [15]. Other factors 
that have been investigated for their possible contributions to the onset of celiac 
disease include (1) time and amount of gluten consumption in infants [16–18], 
(2) virus infection [19, 20], (3) H. pylori eradication [21, 22], (4) maternal gluten 
consumption [23], (5) maternal C-section [24–26], (6) maternal iron deficiency  
[27, 28], (7) summer birth [29–31], (8) maternal high education [32], (9) maternal 
non-smoking [33], (10) high socio-economic status [34, 35], (11) geographic 
locations [36–38], (12) Vitamin D deficiency [39], (13) antibiotic use in childhood 
[40], and (14) PPI use [41]. However, none of these factors are sufficient to solve 
the puzzle completely. It seems that each one of these factors plays a part but they 
(at least some of them) must work together to trigger the intestinal allergy to gluten 
and the subsequent clinical manifestations of celiac disease.
While many years of effort has been made, the pathogenesis of celiac disease still 
remains as a mystery today.
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3. Current therapeutic strategies for celiac disease
Since celiac disease is troubling at least 1% of the world population, people have 
been actively searching for therapeutic solutions to control the disease. The effort 
has been focusing on each key component in the entire pathogenic process, which 
can be classified into the following five categories.
3.1 Reduction of gluten immunogenicity
The simplest way that one can think of to cure celiac disease is to stop eating all 
gluten-containing food. Without the trigger, the disease of course will never occur. 
Believe it or not, this is the most effective method thus far to treat celiac disease – a 
gluten-free diet. However, wheat products have been the main component of our 
daily meals for thousands of years, not only for the Western world but also for the 
Orientals. The only difference between the western bread and the eastern bread is 
that the former is baked and the latter is steamed. Quitting such a lifestyle for most 
people is hard to do. For this reason, scientists have been trying to engineer wheat 
genetically so that it will produce flour containing less or not all gluten without los-
ing much of the original gastronomic properties. Unfortunately, this has not been 
very successful so far [42, 43].
3.2 Prevention of gluten degradation
The idea is to use synthetic polymers or specific antibodies to sequester gluten 
in the gut so that it would not be degraded into an immunogen. BL-7010 is such a 
polymer. In vitro analyses as well as animal studies all showed promising results, 
including no toxicity [44], gluten selectivity [45], and villous protection [46]. Now 
its clinical trials are underway. Using antibodies to seize gluten in the intestine has 
also gained encouraging results. AGY is an IgY antibody generated from chicken 
eggs against gluten. Taking AGY capsules has been shown capable to reduce gliadin 
absorption from 42.8% to 0.7% in an animal study [47]. A clinical trial with AGY 
also obtained effectiveness [48].
3.3 Prevention of gluten peptides entering intestinal mucosa
The next target is intestinal epithelial integrity. The majority of gluten peptides 
get to the lamina propria through para-cellular space, which is sealed by tight 
junctions in healthy individuals. Overexpression of zonulin triggered by gluten 
stimulation in DQ2/DQ8 carriers causes a collapse of the tight junctions. Therefore, 
if mucosal permeability is restricted, gluten peptides will largely remain in the 
intestinal lumen. Larazotide acetate is an octa-peptide developed against zonulin. 
Phase I and II clinical trials all showed substantial improvement in clinical symp-
toms, although some patients had some minor side-effect, such as headache and 
urinary infections [49–52].
3.4 Inhibition of tissue transglutaminase
As mentioned above, the immunogenicity of gluten peptides in celiac disease 
patients is largely dependent on their deamidation by tTG-2. Therefore, inhibi-
tion of tTG-2 activity would reduce the amount of immunogen production. 
Because tTG-2 activation also contributes to several other diseases, such as 
Parkinson’s, Alzheimer’s, Huntington’s, and even some cancers, a great effort 
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encouraging results using this strategy in the treatment of celiac disease. A phase 
II clinical trial has been initiated.
3.5 Prevention of immune reaction
Celiac disease is an autoimmune disorder. The therapeutic strategies discussed 
above all intend to stop gluten from becoming an immunogen. The last approach 
is targeting the immune reaction assuming the four strategies above all failed. 
This includes using chemical blockers to mask the active sites of DQ2, using 
immunodominant gluten peptides to vaccinate DQ2/DQ8 carriers, transplanting 
special bacteria that are capable to produce nontoxic gluten in the human gut, using 
steroids, etc. Many such products will be out soon.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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